Cipla 과거 순이익 실적
과거 기준 점검 2/6
Cipla은 연평균 17.3%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 14.4% 증가했습니다. 매출은 연평균 7.6%의 비율로 증가했습니다. Cipla의 자기자본이익률은 11.2%이고 순이익률은 13.9%입니다.
핵심 정보
17.31%
순이익 성장률
17.28%
주당순이익(EPS) 성장률
| Pharmaceuticals 산업 성장률 | 17.49% |
| 매출 성장률 | 7.61% |
| 자기자본이익률 | 11.19% |
| 순이익률 | 13.94% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • Jun 05
CIPLA: Fair Outlook As New CEO And Respiratory Portfolio Changes Take Shape
Analysts have raised their price target on Cipla by about ₹30 to ₹1,459.57, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple, alongside a marginally higher discount rate. What's in the News Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases like COPD and asthma.분석 기사 • May 16
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...내러티브 업데이트 • Apr 27
CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook
Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.내러티브 업데이트 • Apr 12
CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook
Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).내러티브 업데이트 • Mar 27
CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook
Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).내러티브 업데이트 • Mar 13
CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook
Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).내러티브 업데이트 • Feb 27
CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook
Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).내러티브 업데이트 • Feb 13
CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations
Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).내러티브 업데이트 • Jan 30
CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential
Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).분석 기사 • Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...분석 기사 • Jan 17
The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet
With a price-to-earnings (or "P/E") ratio of 20.7x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...내러티브 업데이트 • Jan 16
CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential
Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).분석 기사 • Dec 29
We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Nov 20
Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...분석 기사 • Sep 24
Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 22.9x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...분석 기사 • Sep 06
Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...내러티브 업데이트 • Sep 04
Emerging Markets And Chronic Therapies Will Open New Horizons
With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.분석 기사 • Jul 13
Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
새로운 내러티브 • Nov 10
Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions
Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.매출 및 비용 세부 내역
매출 및 비용 세부 내역
Cipla가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 278,278 | 38,792 | 67,750 | 0 |
| 31 Dec 25 | 279,672 | 45,464 | 64,591 | 0 |
| 30 Sep 25 | 279,658 | 54,411 | 63,317 | 0 |
| 30 Jun 25 | 274,796 | 53,925 | 62,248 | 0 |
| 31 Mar 25 | 272,674 | 52,725 | 61,067 | 0 |
| 31 Dec 24 | 267,201 | 49,897 | 58,640 | 0 |
| 30 Sep 24 | 262,642 | 44,751 | 57,345 | 0 |
| 30 Jun 24 | 258,922 | 43,035 | 56,178 | 0 |
| 31 Mar 24 | 255,367 | 41,216 | 54,901 | 0 |
| 31 Dec 23 | 251,163 | 37,082 | 53,757 | 0 |
| 30 Sep 23 | 243,407 | 34,532 | 52,563 | 0 |
| 30 Jun 23 | 235,108 | 31,112 | 51,260 | 0 |
| 31 Mar 23 | 225,593 | 28,019 | 50,151 | 0 |
| 31 Dec 22 | 222,187 | 26,383 | 48,947 | 0 |
| 30 Sep 22 | 218,874 | 25,660 | 48,184 | 0 |
| 30 Jun 22 | 216,105 | 24,884 | 35,984 | 0 |
| 31 Mar 22 | 217,078 | 25,168 | 46,669 | 0 |
| 31 Dec 21 | 210,718 | 25,681 | 43,285 | 0 |
| 30 Sep 21 | 207,616 | 25,876 | 43,004 | 0 |
| 30 Jun 21 | 202,801 | 25,417 | 42,435 | 0 |
| 31 Mar 21 | 191,205 | 24,049 | 41,281 | 0 |
| 31 Dec 20 | 188,779 | 22,374 | 40,432 | 0 |
| 30 Sep 20 | 180,802 | 18,403 | 39,444 | 0 |
| 30 Jun 20 | 174,377 | 16,462 | 38,851 | 0 |
| 31 Mar 20 | 170,805 | 15,465 | 38,694 | 0 |
| 31 Dec 19 | 171,206 | 16,678 | 38,608 | 0 |
| 30 Sep 19 | 167,572 | 16,489 | 38,331 | 0 |
| 30 Jun 19 | 163,733 | 15,546 | 37,837 | 0 |
| 31 Mar 19 | 163,232 | 15,277 | 37,415 | 0 |
| 31 Dec 18 | 155,224 | 13,391 | 35,683 | 0 |
| 30 Sep 18 | 154,287 | 14,074 | 35,078 | 0 |
| 30 Jun 18 | 154,992 | 14,530 | 34,564 | 0 |
| 31 Mar 18 | 151,053 | 14,105 | 34,151 | 0 |
| 31 Dec 17 | 147,618 | 11,701 | 32,973 | 0 |
| 30 Sep 17 | 144,951 | 11,444 | 32,730 | 0 |
| 30 Jun 17 | 141,637 | 10,762 | 32,875 | 0 |
| 31 Mar 17 | 143,340 | 10,064 | 33,011 | 0 |
| 31 Dec 16 | 142,509 | 11,213 | 31,554 | 0 |
| 30 Sep 16 | 137,547 | 10,071 | 31,012 | 0 |
| 30 Jun 16 | 134,335 | 12,219 | 30,089 | 0 |
| 31 Mar 16 | 135,480 | 13,600 | 29,258 | 0 |
| 31 Dec 15 | 135,044 | 16,847 | 39,028 | 1,120 |
| 30 Sep 15 | 131,633 | 16,694 | 38,220 | 1,120 |
| 30 Jun 15 | 124,782 | 15,368 | 37,096 | 1,120 |
양질의 수익: CIPLA는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: CIPLA의 현재 순 이익률 (13.9%)은 지난해 (19.3%)보다 낮습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: CIPLA의 수익은 지난 5년 동안 연평균 17.3% 증가했습니다.
성장 가속화: CIPLA은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.
수익 대 산업: CIPLA은 지난 1년 동안 수익이 감소(-26.4%)하여 Pharmaceuticals 업계 평균(15.8%)과 비교하기 어렵습니다.
자기자본이익률
높은 ROE: CIPLA의 자본 수익률(11.2%)은 낮음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/22 15:13 |
| 종가 | 2026/06/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Cipla Limited는 55명의 분석가가 다루고 있습니다. 이 중 36명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |